# Exploring the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures

> **NCT00416195** · PHASE2 · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** E2007
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00416195
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2008-02
- **Final completion:** 2008-03
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2014-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00416195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00416195, "Exploring the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00416195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*